Cell-Easy Expands US Footprint with Key Contract Signing for Master Cell Bank (MCB) and Working Cell Bank (WCB) Manufacturing Services.

Toulouse, France, May 14, 2024 –

Cell-Easy, a European Contract Development and Manufacturing Organization (CDMO) specializing in Cell Therapy, announces a significant milestone with the signing of a Cell Bank Development and Manufacturing services contract with a prominent US-based pharmaceutical company. This partnership solidifies its position as a trusted expert in cell-based product development and manufacturing services.

Human cell banking plays a critical role in advancing cell-based therapies, serving as the foundation for product development, regulatory approval, and commercialization. However, the process presents challenges, including maintaining cell viability, ensuring genetic stability, and adhering to stringent regulatory requirements. Addressing these challenges requires expertise in cell culture, cryopreservation, and quality control, along with access to validated providers and scalable manufacturing capabilities.

Cell Easy was chosen for its expertise in the above-mentioned fields:

• • • • Track record in Cell-Banking: With numerous Cell Banking projects in different cell types using various technologies, Cell-Easy had the track record to convince on its ability to scale-up the process and safeguard cells using the suitable freezing strategy.
      • Managing international supply chains: Cell-Easy has established a network of validated providers to ensure the safe and efficient delivery of cell products, even cross-Atlantic.
      • Competitive Costs: Finding the best path forward, Cell-Easy’s process development experts have been able to streamline the process, reducing the overall costs without compromising on quality. Reduction in manpower, raw material and clean room booking have all been instrumental in providing cost-effective solutions while maintaining the highest standards of excellence in cell bank manufacturing.